# SENTRI: THE SENTINEL MANIFESTO
## A Research-Driven Blueprint for Decentralized AMR Intelligence in Sub-Saharan Africa

**Project Name:** SENTRI (Sentinel Emergency Network for Treatment & Resistance Intelligence)  
**Revision:** 1.0.0-RESEARCH-ALPHA  
**Status:** Active Research Phase  

---

### EXECUTIVE SUMMARY: THE ACTIVE PANDEMIC
As of 2024-2026, Antimicrobial Resistance (AMR) has evolved from a clinical concern into a full-scale health security threat in Sub-Saharan Africa (SSA). The Africa CDC and WHO have officially categorized AMR as a "silent pandemic" that kills more people on the continent than HIV, Tuberculosis, and Malaria combined. 

The fundamental failure is not just biological; it is an **informational infrastructure collapse**. 

In the high-income West, AMR is monitored through integrated Electronic Health Records (EHR) and standardized laboratory testing. In Africa, 60-80% of healthcare encounters occur in the **Informal Sector**. When a mother in a rural village or an urban slum buys antibiotics from a street vendor or a small unlicensed pharmacy, that event is invisible to the state. This "Data Vacuum" allows resistant superbugs to evolve, mutate, and spread in total darkness. By the time these cases arrive at a tertiary hospital, the resistance is already widespread, and the chance for containment is lost.

**SENTRI** is the decentralized response. It is a framework designed to sense the emergence of resistance at the grassroots level and provide the "antibodies" of clinical guidance in real-time.

---

### I. THE EMPIRICAL CRISIS: AFRICAN AMR LANDSCAPE (2024-2026)

#### 1.1 The Mortality Burden
Data from late 2024 and early 2025 indicates that SSA maintains the highest AMR-attributable mortality rate globally, at **27.3 deaths per 100,000 people**. If left unchecked, the death toll is projected to reach **4.1 million per year by 2050**. This is not a distant threat; it is an active drain on the continent's human and economic capital, costing an estimated **$1 trillion in GDP loss** by 2030.

#### 1.2 The Diagnostic Desert
The core of the problem lies in laboratory capacity. A 2024 survey by the African Society for Laboratory Medicine (ASLM) found that **less than 2% of medical laboratories** in 14 surveyed countries have the capacity to perform even the most basic bacteriology culture and sensitivity testing. Without diagnostics, clinicians are forced into "Empiric Treatment"—guessing which drug might work. This creates a vicious cycle: incorrect guesses lead to treatment failure, which in turn selects for the most resistant bacteria, accelerating the evolution of superbugs.

#### 1.3 The Informal Market Dynamics
In urban centers like Lagos, Nairobi, and Kinshasa, the "Patent Medicine Vendor" (PMV) is the primary healthcare provider. These vendors operate without digital tools, selling drugs over the counter without prescriptions. Their sales data is the "Missing Link" in global surveillance. SENTRI targets this gap by turning every feature phone and smartphone into a data sensor.

---

### II. THE SENTRI ARCHITECTURE: ELITE INTELLIGENCE AT THE EDGE

SENTRI does not rely on a centralized, high-bandwidth cloud. It is built for the "Last Mile."

#### 2.1 Multimodal Ingestion (The Eyes & Ears)
We leverage a tiered ingestion strategy to ensure 100% coverage:
- **Level 1 (Feature Phones):** USSD and SMS interfaces for structured data entry (e.g., `*SENTRI*DrugID*Symptom#`).
- **Level 2 (Smartphones):** AI-powered Camera OCR. A vendor snaps a photo of a handwritten prescription or a drug package. Agent A extracts the dosage, duration, and patient symptoms instantly.
- **Level 3 (Voice):** Multilingual ASR (Automatic Speech Recognition) for traditional healers and CHWs who prefer verbal reporting in local dialects.

#### 2.2 The Multi-Agent Intelligence Pipeline
SENTRI deploys three specialized AI agents operating in a coordinated "Sentinel Loop":
- **Agent A (Syndromic Ingestion):** The "Linguist." It normalizes unstructured data (OCR/ASR) into a structured clinical schema.
- **Agent B (Pattern Analyzer):** The "Strategist." It applies Bayesian inference to correlate ingestion data with available lab results and wastewater surveillance, predicting resistance probability in a 5km radius.
- **Agent C (Guidance & Alert):** The "Guardian." It delivers real-time, localized treatment advice back to the field workers via Push Notifications or SMS.

---

### III. THE SENTRI TIERED INTELLIGENCE ARCHITECTURE (STIA)

Following the 2025-2026 research into NPU-acceleration, SENTRI implements a **Sovereign Mesh** model:
1. **The Oracle (Tier 1 - District Hub):** NVIDIA Jetson AGX Thor running **OpenMedLLM-70B**. Handles deep reasoning and cross-district trend analysis.
2. **The Sentinel (Tier 2 - Clinic Node):** NVIDIA Jetson Orin Nano Super running **MedGemma-27B**. Real-time OCR and clinic-level guidance.
3. **The Field (Tier 3 - Mobile Node):** Llama-3.2-3B running locally on smartphones or Hailo-accelerated handhelds for instant syndromic capture.

---

### IV. THE 17-PHASE STRATEGIC ROADMAP (REVISED 2026)

#### PHASE 00: THE SENTINEL MANIFESTO (INDEX & CORE VISION)
Setting the vision: Health Sovereignty through Decentralized Intelligence.

#### PHASE 01: THE DATA VACUUM ANALYSIS (AFRICAN AMR LANDSCAPE)
Validating the "Blind Spots" in GLASS and Africa CDC surveillance using 2024-2025 mortality data.

#### PHASE 02: THE ELITE RESEARCH REPORT (MODEL & HARDWARE SELECTION)
Evaluating OpenMedLLM, MedGemma, and Jetson/Hailo silicon for the STIA stack.

#### PHASE 03: ZENOH MESH PROCOTOL (DECENTRALIZED SYNC)
Architecture for P2P data synchronization where internet infrastructure is unreliable.

#### PHASE 4: MULTIMODAL INGESTION (INDUSTRIAL OCR/ASR)
Developing TensorRT-accelerated pipelines for scanning pharmacy notes and drug packs.

#### PHASE 05: SOVEREIGN RAG (LOCALIZED CLINICAL KNOWLEDGE GRAPH)
Vectorizing 54 African National Essential Medicine Lists (EMLs) and informal market trends.

#### PHASE 06: BEYESIAN PATTERN ANALYZER (AGENT B SPEC)
Probabilistic modeling of resistance clusters under high uncertainty and reporting bias.

#### PHASE 07: CLOSED-LOOP GUIDANCE (AGENT C ALERTING)
Automated SMS/Voice and Push alerts adapted to local drug availability.

#### PHASE 08: RUST CORE DEVELOPMENT (ZENOH BUS)
Building the sub-millisecond data bus for edge-to-edge communication.

#### PHASE 09: NPU QUANTIZATION (INT4/GGUF DEPLOYMENT)
Optimizing Llama-3.2 and MedGemma for Jetson/Hailo silicon.

#### PHASE 10: PRIVACY-FIRST PROTOCOL (ANONYMIZED HEALTH IDS)
Implementing Differential Privacy at the ingestion layer to protect patient identity.

#### PHASE 11: GEOSPATIAL HEATMAPPING (GIS INTEGRATION)
Visualizing resistance "Hotspots" for district health authorities.

#### PHASE 12: FIELD MOBILE SUITE (FLUTTER/DART)
High-performance field application for CHWs and informal pharmacists.

#### PHASE 13: AUTHORITY WEB SUITE (REACT/D3)
High-fidelity dashboards for national health surveillance centers.

#### PHASE 14: SYSTEM INTEGRATION & MESH TESTING
Validating the STIA pipeline across Tier 1, 2, and 3 nodes.

#### PHASE 15: FIELD PILOT & VALIDATION (SANGER INSTITUTE DATA)
Calibrating Agent B against ground-truth genomic resistance profiles.

#### PHASE 16: SCALING & PAN-AFRICAN ADVOCACY
Alignment with Africa CDC's "New Public Health Order" for continental deployment.

---

### V. CONCLUSION
SENTRI is not a prototype; it is an **Immune System** for a continent. By merging elite NPU-accelerated AI with Swahili-derived logic and African-specific clinical research, we are closing the data vacuum once and for all.

**The best is in our hands.**

